Berry Genomics

Berry Genomics, established in May 2010, is an innovative biotechnology company that centers on independent research and development. It has consistently committed itself to the comprehensive transformation of gene sequencing technology into clinical applications, promoting the advancement of precision medicine. At the same time, it continuously explores the effective application of gene sequencing technology across multiple fields, advancing cutting-edge research in life sciences. The company always adheres to a spirit of proactive innovation and determination, focusing on clinical needs and relying on precise testing technologies, innovative bioinformatics analysis, professional genetic counseling, and a rigorous scientific attitude to ultimately achieve the goal of serving human health.As a pioneering enterprise in China’s gene testing industry, Berry Genomics introduced non-invasive prenatal DNA testing (NIPT) to China and successfully commercialized it, laying a solid foundation for the broader application of gene sequencing technology in clinical settings. Berry Genomics continues to deepen the application of gene testing technology in reproductive health, genetic diseases, and oncology, with particularly substantive progress achieved in early cancer diagnosis and screening.Berry Genomics has brought together a group of outstanding multidisciplinary experts and maintains close cooperation and exchanges with top-tier scientific research institutes, universities, and medical institutions both domestically and internationally. This allows the company to further highlight its advantages in product development, bioinformatics analysis, genetic counseling, and big data application.